Skip to main content
. 2017 Mar 3;12(3):e0173201. doi: 10.1371/journal.pone.0173201

Table 6. Predictors of evolution to stage ≥4 CKD in patients with PLA2R-related PMN.

CKD ≥ 4 (N = 13) CKD < 4 (N = 49)
P50 [P25 ; P75]
n* n* p-value
Age atdiagnosis(years) 13 69.2 [58.2; 78.2] 49 51.5 [38.0;59.8] 0.0024
Atdiagnosis
PLA2R-Ag 12 46 1
    Positive 12 (100) 44 (95.7)
    Negative 0 (0) 2 (4.3)
Proteinuria (g/d) 13 9.2 [7.7; 14.5] 49 6.0[3.5; 9.7] 0.0300
eGFR (mL/min) 13 61.0 [35.0; 68.0] 49 87.0 [58.0;101.0] 0.0090
Serum albumin (g/L) 13 19.5 [16.9; 26.0] 49 20.0 [16.0; 26.0] 0.9588
PLA2R-Ab (RU/mL) 11 377.3 [313.9; 754.6] 42 45.2[0.0; 210.4] 0.0012
PLA2R-Ab serology 11 41 0.0930
    Negative 0 (0.0) 11 (26.2)
    Positive 11 (100) 30(73.2)
At 6 months
Protéinuria (g/d) 11 8.0[1.3; 13.3] 32 4.8[2.5; 7.4] 0.1842
eGFR (mL/min) 11 31.0 [11.0; 52.0] 31 77.0 [55.0; 109.0] 0.0004
Serum albumin (g/L) 10 22.0[19.0; 30.1] 30 24.0 [20.0; 29.0] 0.6713
PLA2R-Ab (RU/mL) 6 343.2 [72.0; 671.1] 29 35.0 [0.0; 82.8] 0.0091
PLA2R-Ab serology 6 29 0.1519
    Negative 0 (0.0) 10 (34.5)
    Positive 6 (100) 19(65.5)
End of follow-up 31.5 [23.5 ; 44.9] 31.8 [19.9 ; 570] 0.8162
Proteinuria (g/d) 11 1.0 [0.8; 6.4] 46 0.5[0.3; 1.8] 0.0578
eGFR (mL/min) 12 11.0 [1.0; 25.0] 46 79.0 [64.0; 100.0] <0.0001
Serumalbumin (g/L) 7 35.0 [28.4; 38.0] 44 38.0 [33.0; 405] 0.3284
PLA2R-Ab (RU/mL) 9 49.3 [16.1; 277.0] 37 0.0 [0.0; 0.0] 0.0015
PLA2R-Ab serology 9 37 0.0029
    Positive 7 (77.8) 8 (21.6)
    Negative 2 (22.2) 29 (78.4)
Ab disappearance 9 26 0.0030
    No 7 (77.8) 5(19.2)
    Yes 2 (22.2) 21 (80.8)

* number of patients.

Frequencies (percentage) or medians (interquartile range) are shown. Quantitative variables were compared by a Student’s t-test or a Wilcoxon rank-sum test, and categorical variables were compared by a Pearson's Chi-squaretest or Fisher’s exact test.